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The transporter associated with antigen processing (TAP) selectively translocates 
 antigenic peptides into the endoplasmic reticulum. Loading onto major histocompatibility 
complex class I molecules and proofreading of these bound epitopes are orchestrated 
within the macromolecular peptide-loading complex, which assembles on TAP. This 
heterodimeric ABC-binding cassette (ABC) transport complex is therefore a major 
component in the adaptive immune response against virally or malignantly transformed 
cells. Its pivotal role predestines TAP as a target for infectious diseases and malignant 
disorders. The development of therapies or drugs therefore requires a detailed com-
prehension of structure and function of this ABC transporter, but our knowledge about 
various aspects is still insufficient. This review highlights recent achievements on the 
structure and dynamics of antigenic peptides in complex with TAP. Understanding the 
binding mode of antigenic peptides in the TAP complex will crucially impact rational 
design of inhibitors, drug development, or vaccination strategies.
Keywords: ABC transporter, antigen processing, ligand binding, membrane proteins, peptide-loading complex, 
substrate-binding site
iNTRODUCTiON
Our human body is continually threatened by billions of potential pathogens, e.g., bacteria, viruses, 
fungi, and parasites. Thus, a multilayered defense has evolved to protect vertebrates from these 
pathogens by sophisticated mechanisms. Physical and chemical barriers, such as skin or gastric 
juice, are the primary, non-specific protective shields preventing the pathogens from entering the 
host organism. Pathogens able to pass this first barrier are combated by the innate immune system as 
the secondary protective shield reacting with an immediate, pathogen-oriented response mediated 
by immune cells, such as macrophages, granulocytes, and natural killer cells, or the plasma protein 
cascade of the complement system. As third layer of defense, the adaptive immune system recognizes 
antigens and mounts an immunological memory. Adaptive immunity acts via a humoral and cellular 
response. The humoral, antibody-mediated response depends on the antigen/pathogen recognition 
by B-lymphocytes within the lymph or blood. However, the cellular path of adaptive immunity 
utilizes T-lymphocytes recognizing antigenic peptides presented by major histocompatibility com-
plexes (MHC). This pathway has regulatory and cytotoxic functions (1).
Antigen presentation can be subdivided into MHC class I and MHC class II dependent pathways. 
Antigenic peptides derived from exogenous antigens are loaded in lysosomal-like compartments 
on MHC II molecules and are finally presented to CD4+ T helper lymphocytes (2, 3). Endogenous 
antigens are degraded via the ubiquitin/proteasome and other proteolytic pathways. Degradation 
products can be translocated into the lumen of the endoplasmic reticulum (ER) by the transporter 
associated with antigen processing (TAP). A peptide-loading complex (PLC), composed of TAP1 
FigURe 1 | Structural organization of the antigen translocation complex transporter associated with antigen processing (TAP). (A) 3D homology model 
of the human TAP complex based on the TAP-related heterodimeric ABC-binding cassette transporter TmrAB in the inward-facing conformation (13, 14). The 
heterodimeric translocation machinery (TAP1 and TAP2) consists of a 2 × 6 TMHs core domain, two additional N-terminal four-transmembrane helix bundles 
(TMD0, schematically shown), and two nucleotide-binding domains (NBDs). Core transmembrane domains (TMDs) and TMD0s are connected via elbow helices 
(EHs). Two NBDs facilitate ATP binding and hydrolysis. (B) Top view from the ER lumen along the TMD–NBD interface. Coupling helix CH1 mediates inter-domain 
cross talk between NBDs and TMDs in cis and in trans, whereas CH2 interacts in trans. (C) Schematic view of the asymmetric NBDs of the TAP complex. NBDs are 
tightly packed in the outward-facing conformation and thus form two ATP-binding sites. The presence of non-equivalent, consensus and non-consensus ATPase 
sites is based on aberrant amino acid residues within the conserved sequence motifs. TAP1: gray, TAP2: blue, CH/EH: raspberry.
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and TAP2, the two ER chaperones, tapasin, and calreticulin, the 
oxidoreductase ERp57 together with MHC I heavy chain and 
β2-microglobulin, is essential for efficient loading of antigenic 
peptides onto MHC I molecules. After epitope proofreading and 
quality control within the PLC, kinetically stable peptide–MHC 
complexes are released to shuttle their antigenic cargo via the 
secretory pathway to the plasma membrane. At the cell surface, 
MHC I molecules present their antigenic peptides to CD8+ cyto-
toxic T-lymphocytes, which eventually induce the elimination of 
virally or malignantly transformed cells (2, 3). Cross-presentation 
is a subtype of MHC I-dependent antigen presentation but 
mediated by efficient uptake and processing of exogenous anti-
gens. Two main pathways for cross-presentation are proposed. 
However, the exact mechanistic details are still unclear. While the 
cytosolic pathway is proteasome- and TAP-dependent, the vacu-
olar pathway depends on neither the proteasome nor TAP (4).
The fundamental role of the transport complex TAP within 
the adaptive immunity predestinates TAP as a target for infec-
tious diseases and malignant disorders, such as bare lymphocyte 
syndrome type I and cancer. Detailed knowledge about the TAP 
structure and transport mechanism is thus of capital importance 
for the development of therapies or drugs against such diseases, 
but numerous aspects are insufficiently identified to date. This 
review focuses on the structure and dynamics of antigenic pep-
tides bound to TAP, shedding light on recent efforts to determine 
the structure of a bound substrate and to localize its respective 
binding site by biophysical and theoretical methods, such as elec-
tron paramagnetic resonance (EPR), nuclear magnetic resonance 
(NMR), and molecular docking experiments.
STRUCTURAL ARRANgeMeNT OF THe 
HUMAN TAP COMPLeX
TAP1 and TAP2 are members of the ABC-binding cassette (ABC) 
subfamily B (ABCB2 and ABCB3) and found in all nucleated cells 
of jawed vertebrates. TAP is predominantly located in the ER and 
cis-Golgi, although an ER-targeting or ER-retention signal has 
not been specified to date (5). A heterodimeric TAP complex 
is essential and sufficient for peptide binding and transloca-
tion, whereas TAP1 or TAP2 homodimers are non-functional 
(6, 7). TAP consists of two transmembrane domains (TMDs) 
harboring the substrate-binding site and two nucleotide-binding 
domains (NBDs) responsible for ATP binding and hydrolysis 
(Figure 1A). Each half-transporter contains an N-terminal four-
transmembrane helix bundle, termed TMD0. A conserved salt 
bridge between the TMD0 and tapasin located within the ER 
membrane was found to be essential for PLC assembly and for 
an efficient antigen processing (8, 9). In contrast, the core TAP 
subunits lacking these TMD0s are sufficient for TAP assembly, ER 
targeting, peptide binding, and peptide translocation (8, 10). The 
core transporter and the TMD0s are connected by elbow helices 
(EHs), whose function is still undefined. The coupling helices 
CH1 and CH2, located in the cytosolic loops (CLs) between TM2 
and TM3 as well as TM4 and TM5, allow a cross talk between the 
TMDs and the NBDs in cis and in trans. They are embedded into 
a groove between the RecA-like and the α-helical domains of the 
NBD, thereby interacting with the Q- and X-loop as well as the 
NBD region, which positions the purine base of ATP (Figure 1B) 
(11, 12).
FigURe 2 | Current model of the translocation cycle of peptides by transporter associated with antigen processing (TAP). Under physiological 
conditions, TAP is loaded with ATP in an inward-facing conformation. Binding of a peptide (step 1) induces a conformational rearrangement of the TAP complex and 
subsequently nucleotide-binding domain dimerization. Presumably, an occluded state is formed (step 2) followed by a switch to an outward-facing conformation 
triggering peptide translocation across the membrane (step 3) and subsequent release of the peptide into the endoplasmic reticulum (ER) lumen (step 4). ATP 
hydrolysis (step 5) resets the TAP complex back in its resting state and ADP is exchanged against ATP (step 6). At high ER-lumenal peptide concentrations (16 µM), 
TAP is blocked by trans-inhibition.
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Several conserved motifs, such as Walker A, Walker B, ABC 
signature (C-loop), A-/D-/Q-loop, and H-switch, are character-
istic for ABC proteins. The X-loop is an additional conserved 
region but only present in some ABC exporters, such as TAP. 
Cysteine-scanning and cross-linking approaches revealed that 
both coupling helices interact in trans with the X-loop of the 
opposite subunit (TEVDEAG and TDVGEKG; conserved 
glutamate in bold). The transport activity was reduced without 
affecting peptide binding, when the conserved glutamate of the 
X-loop in TAP2 was mutated. Cross-linking the X-loop with 
either CH1 or CH2 impedes substrate transport or binding, 
respectively (11, 12).
The non-equivalence of the two nucleotide-binding sites (NBS 
I and II), each coordinating an ATP molecule by both NBDs, is 
an intriguing feature common to many human ABC transporters 
including TAP (Figure 1C). In TAP1, the conserved glutamate 
next to Walker B, acting as catalytic base, is replaced by aspartate 
and the conserved histidine of the H-switch by glutamine. In 
addition, the signature motif (C-loop) of TAP2 differs by two 
residues (LSGGQ to LAAGQ). Altered residues are exclusively 
located at NBS I, which displays a strongly diminished ATPase 
activity. NBS I is hence qualified as a non-consensus site. The role 
of this degenerate NBS in ABC transporters is still enigmatic. 
However, a peptide-specific trapping of an ATP hydrolysis transi-
tion state at both NBS can only be observed after one cycle of ATP 
hydrolysis and not in a backward reaction in the presence of ADP 
and trapping reagent (15). Nonetheless, a mutated TAP complex 
harboring two degenerate C-loops shows a drastically diminished 
transport rate. Thus, NBS I seems to adopt a regulatory role, while 
the consensus site constitutes the driving motor for substrate 
transport by TAP. This was supported by an increase in transport 
activity for a chimera with two canonical C-loops (16, 17).
TRANSPORT MeCHANiSM OF PePTiDeS 
BY TAP
Details of the transport mechanism and conformational dynam-
ics of the TAP transporter have not been elucidated adequately to 
date. The current working model of the translocation mechanism 
of peptides by TAP was derived from biochemical approaches 
and recent structures of ABC exporters, which share a similar 
overall architecture (Figure 2). The TMDs of the TAP complex 
seal the pathway to the ER lumen in the inward-open conforma-
tion. Peptide binding to the TMDs occurs independently from 
ATP binding to the NBDs, which are separated from each other 
(15–17). Under physiological conditions, the transport complex 
is loaded with two ATP-Mg in the resting state. Peptide binding 
of TAP triggers an allosteric cross talk between NBDs and TMDs 
transmitted by the coupling helices. The adopted substrate-bound 
state induces dimerization of the NBDs and presumably the 
formation of an occluded state. A subsequent conformational 
rearrangement of the TMDs switches TAP from the inward-
facing state to the outward-facing state. The tight NBD dimer 
sandwiches two ATP molecules at its interface. As discussed 
above, each ATP molecule is tightly coordinated in the NBS by 
both NBDs (18–20). Notably, ATP hydrolysis by TAP is strictly 
coupled to peptide binding and translocation. No basal ATPase 
activity has been observed in the absence of peptide substrates 
(12, 21, 22). ATP hydrolysis is coupled to the peptide release into 
FigURe 3 | Coevolution of key machineries in the pathway of major histocompatibility complexes (MHC) i antigen processing. Proteasomal 
degradation products with a preferential length and a hydrophobic C terminus are recognized by the transporter associated with antigen processing (TAP) complex 
and translocated into the endoplasmic reticulum (ER) lumen. Peptides, which do not fit into the MHC I binding pocket, are N-terminally trimmed by the ER-resident 
aminopeptidase (ERAP) and subsequently loaded onto MHC I molecules for further processing. The similar C-terminal anchor residues and the overlapping N-to-C 
distance of TAP- and MHC I-bound peptides [(13), PDB: 2BSR] point to a coevolution of both components in antigen processing.
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the ER lumen. After ATP hydrolysis, the NBD dimer is desta-
bilized and the transporter resets to its inward-open, “resting” 
state, in which inorganic phosphate and ADP are exchanged by 
ATP-Mg (23–25).
SUBSTRATe BiNDiNg OF HUMAN TAP
Peptide recognition by TAP is the initial step of the translocation 
cycle followed by allosterically coupled conformational changes 
and ATP hydrolysis. Kinetic analysis of peptide binding revealed 
a two-step process consisting of a fast association and a slow con-
formational rearrangement of the transporter (26). The peptide-
binding process is characterized by a high activation energy and 
involves 25% of all TAP residues (27). Peptide and ATP binding 
occur independently from one another, but peptide binding and 
translocation induce ATP hydrolysis (21). Fluorescence cross-
correlation spectroscopy revealed that only one peptide at a time 
can bind per TAP complex (22). TAP is able to bind peptides 
consisting of 8–16 amino acids with similar nanomolar affinities 
(16). Furthermore, binding of peptides with up to 40 amino acids 
or bulky side chains, such as fluorophores, spin probes, chemical 
proteases, or polylysine chains, is not impeded (21, 28–30). For 
peptide selection by TAP, the first three N-terminal residues and 
the C-terminal peptide residue are critical (17, 28, 29, 31–35). 
The recognition principle of human TAP was investigated by 
applying combinatorial peptide libraries including one defined 
residue in a scanning approach, whereas all other positions are 
fully randomized (36). These studies revealed that human TAP 
favors positively charged (positions 1 and 2) as well as aromatic 
residues (position 3) at the N-terminal positions and hydropho-
bic or basic amino acids at the C terminus of the peptide. Free 
N and C termini are an important prerequisite for high-affinity 
binding (15, 36). The region between these N- and C-terminal 
“anchor” residues can largely vary in sequence and length. EPR 
spectroscopy provided first insights into the dynamics and 
structure of TAP-bound peptides (29). The anchor residues are 
restricted in motion, while residues in-between are highly flex-
ible. Notably, the distance between the N and C termini of the 
TAP-bound peptide was determined to approximately 2.5 nm by 
double electron–electron resonance experiments independently 
of peptide length (29). These data suggest that longer peptides 
accommodate an extended kinked structure in the TAP-bound 
state.
The structurally defined N-to-C distance of TAP-bound 
peptides and the recognition principles indicate a coevolution 
of the immunoproteasome, TAP, and MHC I to improve antigen 
presentation (Figure 3). The immunoproteasome, whose assem-
bly is stimulated by interferon-γ, preferably generates peptides 
equipped with hydrophobic or basic C termini, which are favored 
by TAP (37). The TAP complex translocates these peptides into 
the ER lumen. Longer peptides are N-terminally trimmed by the 
ER-resident aminopeptidase (ERAP) to fragments containing 
mostly eight or nine amino acids. In addition to the favored 
C-terminal residue, these peptides preferentially fit into the MHC 
I binding pocket (38). X-ray crystal structures have shown a fixed 
N-to-C distance of MHC I-bound peptides, defining the minimal 
length of MHC I ligands (39). Thereby, N and C termini of the 
peptide bind to the A and F pockets of the MHC I binding groove. 
A predominant N-terminal anchor residue is located at position 
2, whereas a second hydrophobic anchor residue rests at the C ter-
minus of the peptide (1, 39). T-cell receptors conversely recognize 
peptide residues at positions located between the anchor residues 
of the TAP transporter (40).
Besides the well-characterized high-affinity peptide-binding 
site accessible in the inward-facing conformation, a second, low-
affinity binding site has been proposed based on transport studies 
of TAP reconstituted in proteoliposomes (41). Translocation of 
peptides into proteoliposomes did not exceed a lumenal peptide 
TABLe 1 | essential residues for the functionality of transporter 
associated with antigen processing (TAP).
TAP1 TAP2 Putative 
function
Reference
Peptide 
sensor
G282XL, 
I284XL, R287XL, 
V288XL
– Peptide sensing (28)
Binding 
region
P375-M420XL, 
Q453-R487XL
R354-M389XL, 
I414-M433XL
Peptide binding (42)
Substrate 
specificity
S296XL, 
Y408M, E459XL
C213XL/M, 
T217M, M218M, 
N262M, P265M, 
L266M, A374M, 
R380M
Altering of epitope 
repertoire
(30, 42, 44, 
46, 47)
Functionality E263M – Impaired binding/
transport
(43)
XL/Mresidues of human (black) and rat (blue) TAP derived from cross-linking and 
mutagenesis studies, respectively; all residue numbers refer to human TAP.
FigURe 4 | Residues involved in peptide binding and translocation. 
Cross-linking studies (raspberry) and mutational analyses (blue) revealed 
transporter associated with antigen processing (TAP) residues contributing to 
substrate-binding/translocation (see Table 1). The 3D homology model of the 
human TAP complex is based on the TAP homolog TmrAB in the inward-
facing conformation (13, 14).
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concentration of about 16 µM, although TAP is an active, uni-
directional transporter. This maximal peptide concentration is 
independent from the number of TAP complexes in the mem-
brane. Thus, an inhibition in trans points to a second low-affinity 
binding site facing the ER lumen (Figure  2). Saturation of the 
ER-lumenal peptide-binding site is suggested to impede the 
transporter from switching back to the inward-facing conforma-
tion and inducing another transport cycle. This process, also 
called trans-inhibition, might prevent the induction of ER stress 
and an unfolded protein response at high peptide concentration 
in the ER lumen (41).
SUBSTRATe-BiNDiNg SiTe OF TAP
A number of residues and sequence regions in human TAP are 
critical for peptide binding and transport (Figure  4; Table  1). 
Initial photo-cross-linking studies mapped the peptide-binding 
site within the TMDs of the coreTAP complex, which are con-
fined to the CLs between TMH4 and TMH5 (P375-M420TAP1 and 
R354-M389TAP2) as well as the linker region between the TMD 
and NBD of each half-transporter (Q453-R487TAP1 and I414-
M433TAP2) (42). In addition, residues G282/I284/R287/V288 
within the CL1 of TAP1 were identified as a peptide sensor region 
involved in inter-domain cross talk to allosterically couple peptide 
binding and ATP hydrolysis (28). Furthermore, several residues 
important for substrate specificity were determined. The deletion 
or substitution of E263TAP1 in murine or human cells caused a 
phenotype comparable to TAP1-deficient cells as shown by MHC 
I surface expression. In this TAP mutant, peptide binding and 
translocation are impaired (43). A374 and C213 of TAP2 were 
identified to control the peptide repertoire (42, 44). The replace-
ment of C213TAP2 by serine leads to an altered substrate specificity 
of human TAP. In this mutant, negatively charged peptide residues 
are favored at positions 1, 2, and especially at the C terminus, as 
determined by a scanning approach using combinatorial peptide 
libraries. Cross-linking approaches uncovered the C-terminal 
peptide residues directly contacting C213TAP2 (44). Surprisingly, 
this finding is contradictory to homology models of the TAP 
transporter, in which C213TAP2 points toward the membrane 
bilayer (12, 13, 45, 46). Cross-linking studies and mutational 
analysis on rat TAP derived additional residues within the TAP 
complex, which were suggested to control substrate specificity 
or to contribute to the peptide-binding site. In addition, several 
other residues in TAP2 (A217, E218, Q380, Q262, S265, and L266 
in rat, corresponding to T217, M218, R380, N262, P265, and L266 
in human) were identified to modulate the peptide specificity (30, 
47). Recently, residues C273, Y385, and E436 were determined 
in rat TAP1 (corresponding to S296, Y408, and E459 in human 
TAP) to directly coordinate the bound peptide (46).
Despite the identification of residues presumably contribut-
ing to the substrate-binding site, evaluation of the location of the 
substrate-binding pocket of the TAP complex and detection of 
a peptide epitope within this pocket are challenging. Molecular 
docking approaches were applied to enlighten this aspect. The first 
docking study of the HLA-B27 epitope RRYQKSTEL was based 
on a TAP homology model derived from the homodimeric ABC 
transporter ABCB10 (45). Electrostatic interactions between 
charged peptide residues and the binding pocket itself are like-
wise required for peptide binding, in addition to free N and C 
termini of the peptide. Calculations of electrostatic potentials of 
the predicted binding site indicated the presence of two binding 
pockets. One binding pocket is negatively charged and binds the 
peptide N terminus, while the other is positively charged and 
coordinates the C terminus of the TAP-bound peptide. Here, a 
bound nonamer adopts an extended conformation parallel to the 
membrane plane with an N-to-C distance of 2.2 nm, in line with 
pulsed EPR distance measurements (29). These docking studies 
restrained the TAP interaction sites to the elucidated electrostatic 
binding pockets, while the peptide dynamics was not restricted. 
A second docking study combined recently identified residues 
FigURe 5 | Location of the substrate-binding site within the 
transporter associated with antigen processing (TAP) complex. The 
transmembrane domains position the peptide (dark gray) via its N and C 
termini between TAP1 (gray) and TAP2 (cyan). The extended peptide 
backbone orients in a tilted position with respect to the membrane plane and 
is surrounded by a large cavity (raspberry). The magnification of the 
substrate-binding site illustrates a bound nonamer in a ball-and-stick 
representation (red: O, blue: N, white: H), whereas side chains are only 
shown for one conformer. The 3D homology model of the TAP complex is 
premised on the heterodimeric ABC-binding cassette transporter TmrAB in 
the inward-facing conformation (13, 14).
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with a TAP homology model based on the homodimeric ABC 
transporter Atm1 (46). This study proposed that peptides bind to 
TAP in a β-hairpin-like conformation parallel to the membrane 
plane (46), which is contrary to EPR distance constraints on 
TAP-bound peptides (29) and docking studies (45). Even though 
docking of a double spin-labeled β-hairpin peptide resulted in 
restricted spin labels within the TAP-binding site with an inter-
spin distance of ~2.3  nm (46), this peptide conformation does 
not explain the restriction of TAP-binding peptides to a minimal 
length of eight residues. Therefore, the peptide conformation in 
the TAP-bound state was analyzed by solid-state NMR to clarify 
these controversial results.
Dynamic nuclear polarization-enhanced solid-state NMR 
enabled the elucidation of an extended backbone conformation of 
TAP-bound peptides at an atomic resolution due to a large signal 
enhancement and to significantly reduced data acquisition times 
(13). Molecular docking of the peptide with a restricted backbone 
but freely rotating side chains into a TAP homology model based 
on the heterodimeric ABC transport complex TmrAB revealed 
the peptide bound to TAP in a tilted orientation with respect to 
the membrane plane (Figure 5). Most of the peptide coordinating 
residues of TAP coincided with residues identified by biochemi-
cal methods in previous studies. The obtained backbone structure 
further supports the coevolution of TAP and MHC I molecules 
already discussed above (Figure 3). Chemical shift analyses pro-
vided new insights into the peptide–TAP interaction. The peptide 
is coordinated by TAP at positions 1, 3, and 9. The study further 
unveiled a flexibility of the peptide within its binding site, since 
two distinct binding modes were observed for the N-terminal 
amino group. Interestingly, a large cavity formed by the TMDs 
of both half-transporters can be found next to the binding sites 
of the peptide anchor residues. This cavity may allow accom-
modation of bulky side chains of the peptide and even covalently 
attached fluorophores (Figure 5).
CONCLUDiNg ReMARKS
Several biochemical and theoretical attempts to localize the 
substrate-binding site in the TAP complex now result in a bet-
ter picture of substrate selection by the transporter. Although 
molecular docking approaches provided a useful discernment 
of potential locations for substrate-binding sites, these assays are 
biased by restraining the conformational freedom of the peptide 
and the potential number of hydrogen donors and acceptors. The 
recently elucidated backbone structure and the precise distance 
measurements of the N and C termini of TAP-bound peptides 
provided experimental evidence that significantly improved these 
molecular docking approaches. However, further refinements of 
the positions of the binding pocket(s) by, e.g., pulsed EPR spec-
troscopy are required. These studies will be complemented with 
high resolution X-ray crystallography analyses of peptide–TAP 
complexes. Alternatively, cryo-EM structures may also provide 
valuable insights into the substrate-binding region as demon-
strated for the TAP-related ABC transporter TmrAB (48) and the 
TAP transporter with bound viral inhibitor ICP47 (49).
Unprecedented insights into the dynamics of peptide binding 
and translocation by TAP will be addressed by applying advanced 
biophysical techniques, such as single-molecule Förster resonance 
energy transfer. Together with the depicted peptide-binding site, 
these studies will significantly boost the overall understanding 
of substrate translocation by TAP and thus provide the basis 
to develop novel drugs or therapeutic approaches. Despite the 
wealth of biochemical data on the high-affinity substrate-binding 
site, thermodynamic and kinetic characterization of the low-
affinity binding site is incomplete to date. The substrate specificity 
of the latter site and its location within the TAP complex will 
be of great interest in prospective studies. These investigations 
on the TAP complex will also be pioneering for other ABC 
transporters, such as TAP-like (ABCB9) (50), revealing similar 
trans-inhibitory effects. Moreover, it will be decisive to determine 
how trans-inhibition of TAP helps to balance antigen processing 
as well as ER homeostasis and how these processes are involved in 
the control of ER stress caused by accumulated peptides.
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